Alex Wonnaparhown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alex Wonnaparhown has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Catherine Freeman
Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Phoenix, Ariz
2 shared publicationsJacqueline Squire
Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Jacksonville, Fla
2 shared publications- Rafael Fonseca
Mayo Clinic in Arizona, Phoenix, USA
2 shared publications - Talal Hilal
Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, USA
2 shared publications - Albert C. Chong
Resident in Internal Medicine, Mayo Clinic School of Graduate Medical Education, Scottsdale, AZ, USA
1 shared publication Allison Rosenthal
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Ariz
1 shared publication
Latest Publications
- Open Access
- 10 June 2025
- Published by Elsevier in Blood Reviews
- Vol. 74, 101316
Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions
- 10 June 2025
- Published by Elsevier in Blood Reviews
- Vol. 74, 101316
Open AccessExploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions
- Open Access
- 26 May 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 4 (3) , 100503
Refractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1)
- 26 May 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 4 (3) , 100503
Open AccessRefractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1)
- Open Access
- 25 July 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-9
IgG replacement in multiple myeloma
T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved clinical outcomes, but have also raised awareness for ensuing post-treatment secondary immunodeficiency and hypogammaglobulinemia (HG). As patients with MM live longer, recurrent infections become a significant component of therapy-associated morbidity and mortality. Treatment of HG with immunoglobulin G replacement therapy (IgG-RT) has been a mainstay of the primary immunodeficiency (PI) world, and extrapolation to MM has recently started to show promising clinical outcomes. However, IgG-RT initiation, dosing, route, timing, monitoring, and management in MM has not been standardized in the setting of TCE. Progress in MM treatment will involve greater recognition and screening of underlying secondary immunodeficiency, identification of risk-stratification markers, optimizing IgG-RT management, and implementing other approaches to decrease the risk of infection. In this review, we summarize infection risk, risk of HG, and management strategies for IgG-RT in patients with relapsed MM after TCE.
- 25 July 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-9
Open AccessIgG replacement in multiple myeloma
T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved clinical outcomes, but have also raised awareness for ensuing post-treatment secondary immunodeficiency and hypogammaglobulinemia (HG). As patients with MM live longer, recurrent infections become a significant component of therapy-associated morbidity and mortality. Treatment of HG with immunoglobulin G replacement therapy (IgG-RT) has been a mainstay of the primary immunodeficiency (PI) world, and extrapolation to MM has recently started to show promising clinical outcomes. However, IgG-RT initiation, dosing, route, timing, monitoring, and management in MM has not been standardized in the setting of TCE. Progress in MM treatment will involve greater recognition and screening of underlying secondary immunodeficiency, identification of risk-stratification markers, optimizing IgG-RT management, and implementing other approaches to decrease the risk of infection. In this review, we summarize infection risk, risk of HG, and management strategies for IgG-RT in patients with relapsed MM after TCE.